Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 1.00 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.67 |
| ▸ | MAOA | P21397 | 2/20 | 0.59 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.59 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.59 |
| ▸ | BCHE | P06276 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29666660 | 1.00 | MAOB (1.00) | MAOBMRGPRX4MAOACYP4F2CYP4A11 | |
| SCHEMBL17978716 | 0.98 | MAOB (0.96) | MAOBMRGPRX4MAOACYP4F2CYP4A11 | |
| SCHEMBL4404036 | 0.90 | MAOB (1.00) | MAOBMRGPRX4MAOANPC1ALDH1A1 | |
| SCHEMBL12746077 | 0.90 | MAOB (0.81) | MAOBMRGPRX4MAOACYP4F2CYP4A11 | |
| Bicarbonate SCHEMBL8552113 | 0.89 | MAOB (0.79) | MAOBMRGPRX4MAOACYP4F2CYP4A11 | |
| Bicarbonate SCHEMBL8552114 | 0.89 | MAOB (0.79) | MAOBMRGPRX4MAOACYP4F2CYP4A11 | |
| SCHEMBL13469158 | 0.89 | MAOB (0.82) | MAOBMRGPRX4MAOA | |
| SCHEMBL24628659 | 0.86 | MAOB (0.74) | MAOBMRGPRX4CYP4F2CYP4A11 | |
| SCHEMBL1268719 | 0.86 | MAOB (0.81) | MAOBMAOACYP4F2CYP4A11BCHE | |
| SCHEMBL10046165 | 0.84 | MAOB (0.72) | MAOBMRGPRX4MAOARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 591 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120136886-A | PDE4 inhibitor with pyranonaphthyridone skeleton and preparation method and application thereof | 中山大学 | 2025-06-13 | — | — | CN | claimed |
| WO-2025093057-A1 | METHOD FOR PREPARING METARAMINOL BITARTRATE | 武汉武药制药有限公司 | 2025-05-08 | — | — | WO | claimed |
| CN-119930447-A | Preparation method of meta-hydroxylamine bitartrate | 武汉武药制药有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-118899116-B | Curve heating fire-resistant power cable and preparation method thereof | 广州澳通电线电缆有限公司 | 2025-04-04 | — | — | CN | claimed |
| CN-119504454-A | Synthesis process of meta-hydroxylamine bitartrate | 海南卓科制药有限公司 | 2025-02-25 | — | — | CN | claimed |
| CN-119080710-A | Meta-hydroxylamine bitartrate impurity, synthesis method and application | 上海现代哈森（商丘）药业有限公司 | 2024-12-06 | — | — | CN | claimed |
| CN-118899116-A | Curve heating novel fire-resistant power cable and preparation method thereof | 广州澳通电线电缆有限公司 | 2024-11-05 | — | — | CN | claimed |
| CN-115960003-A | Synthesis method of meta-hydroxylamine bitartrate | 中科苏州药物研究院 | 2023-04-14 | — | — | CN | claimed |
| CN-104016879-B | Dibenzoyl amine compound with anti-tumor activity and its preparation method and application | XI'AN JIAOTONG UNIVERSITY (CN) | 2016-02-24 | — | — | CN | claimed |
| CN-103980153-B | Dibenzoyl amine compound with anti-tumor activity and its preparation method and application | XI'AN JIAOTONG UNIVERSITY (CN) | 2016-01-20 | — | — | CN | claimed |
| CN-104016879-A | Diphenyl amide compound with anti-tumor activity as well as preparation method and application of diphenyl amide compound | UNIV XI AN JIAOTONG | 2014-09-03 | — | — | CN | claimed |
| CN-103980153-A | Biphenyl amide compound with antitumor activity as well as preparation method and application thereof | UNIV XI AN JIAOTONG | 2014-08-13 | — | — | CN | claimed |
| US-12638613-B2 | Ophthalmic lenses and their manufacture by in-mold modification | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| EP-4408852-B1 | ANTHRAQUINONE-FUNCTIONALIZED POLYMERIZATION INITIATORS AND THEIR USE IN THE MANUFACTURE OF OPHTHALMIC LENSES | JOHNSON & JOHNSON VISION CARE (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12577251-B2 | Modulators of the sigma-2 receptor and their method of use | Temple University—Of the Commonwealth System of Higher Education (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | TOPAZ THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-4214084-A | Ethanopyrrolo[1,2-b]isoquinolines | STERLING DRUG INC. (US) | 1980-07-22 | — | — | US | disclosed |
| US-4179567-A | 2-Aryltropane compounds | STERLING DRUG INC. (US) | 1979-12-18 | — | — | US | disclosed |
| US-3992536-A | SEDATIVES AND MUSCLE RELAXANTS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-11-16 | — | — | US | disclosed |
| US-3931185-A | SEDATIVES, MUSCLE RELAXANT | BOEHRINGER INGELHEIM GMBH (DT) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12638613-B2 | Ophthalmic lenses and their manufacture by in-mold modification | UACA, AXL, CRYZ | MAOB 1746/4885MRGPRX4 4100/4885MAOA 838/4885 |
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | RIOX2, ORC3, DCLRE1A | MAOB 3262/4885MRGPRX4 3804/4885MAOA 3534/4885 |
| US-12577251-B2 | Modulators of the sigma-2 receptor and their method of use | SIGMAR1, CHRNA6, NR3C2 | MAOB 1032/4885MRGPRX4 416/4885MAOA 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.